Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LAURUS

Infectious DiseaseRespiratoryCardiovascular

Generics

LAURUS is a generic drug manufacturer focused on Infectious Disease, Respiratory, Cardiovascular. Key products include EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE.

2018

Since

21

Drugs

-

Trials

280

Approved (2yr)

Key Drugs

SACUBITRIL AND VALSARTAN

AT1 receptor 2 indications · 2024

LOPINAVIR AND RITONAVIR

CYP3A 1 indications · 2016

EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

Recent Activity

GABAPENTIN 2026-02-24

GABAPENTIN 2026-02-18

GABAPENTIN 2026-02-17

GABAPENTIN 2026-02-17

GABAPENTIN 2026-02-12

GABAPENTIN 2026-01-29

GABAPENTIN 2026-01-29

OSELTAMIVIR PHOSPHATE 2026-01-22

ATORVASTATIN CALCIUM 2026-01-22

Manufacturing (CMC)

SACUBITRIL AND VALSARTAN 2026-01-20

SEC Filings ProEarly access

Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 33%

2 drugs

Respiratory 33%

2 drugs

Cardiovascular 33%

2 drugs

Pipeline Strength ProEarly access

Loading...

Competitors ProEarly access

GE HEALTHCARE specialty

Infectious Disease, Cardiovascular, Respiratory

APOTHECON specialty

Infectious Disease, Cardiovascular, Respiratory

LEDERLE big-pharma

Infectious Disease, Cardiovascular, Respiratory

Novartis big-pharma

Cardiovascular, Respiratory

Merck big-pharma

Infectious Disease, Cardiovascular